<DOC>
	<DOCNO>NCT02122471</DOCNO>
	<brief_summary>The purpose study confirm investigational medication , plecanatide , safe effective treat chronic idiopathic constipation .</brief_summary>
	<brief_title>12-Week Study Plecanatide CIC ( The National CIC3 Study )</brief_title>
	<detailed_description>This national , randomize , 12-week , double-blind , placebo-controlled , study approximately 1350 adult male female patient CIC compare 2 dos plecanatide placebo . The study conduct approximately 180 clinical study site United States . The primary objective study evaluate efficacy safety 3.0 6.0 mg plecanatide administer daily ( QD ) 12 week population patient CIC . The study population include patient without cause constipation chronic condition could interfere study assessment . Patients may take laxative ( exception study-provided rescue medication , bisacodyl 5mg tablet ) , number prohibit drug know cause constipation diarrhea , study participation . There 6 schedule study visit , include screen follow-up visit . The planned duration participation study 112 day 155 day , washout visit window consider .</detailed_description>
	<mesh_term>Constipation</mesh_term>
	<criteria>Male female age 1880 , inclusive Meets modify Rome III criterion functional chronic idiopathic constipation least 3 month symptom onset least 6 month Completed colonoscopy accordance American Gastroenterological Association ( AGA ) colon cancer screen guideline ( 5 year ) , clinically significant finding Willing maintain stable diet study Loose stool ( mushy ) watery ( Bristol score 6 7 ) stool absence laxative prohibit medicine &gt; 25 % Bowel Movements ( BMs ) 3 month prior screen visit OR 14 day pretreatment assessment Active peptic ulcer disease , diabetes hypertension adequately treat stable History cathartic colon , laxative , enema abuse , ischemic colitis Fecal impaction within 3 month screen Patient /has : disease condition associate constipation ( GI CNS ) , structural abnormality GI tract gastric bypass surgery , pelvic floor dysfunction , pseudoobstruction , active infectious gastritis , diverticulitis , anal fissure disease condition affect GI motility defecation associate abdominal pain Unexplained clinically significant `` alarm symptom '' include low GI bleeding , irondeficiency anemia , weight loss systemic sign infection colitis Major surgery , stroke myocardial infarction ( MI ) within 60 day screen Participated previous plecanatide clinical trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>CIC</keyword>
	<keyword>Constipation</keyword>
	<keyword>Chronic Constipation</keyword>
	<keyword>Synergy</keyword>
	<keyword>Plecanatide</keyword>
</DOC>